

## ACCELERATED COMMUNICATION

# Negative Regulation of Superoxide Dismutase-1 Promoter by Thyroid Hormone

Guilherme M. Santos, Valéry Afonso, Gustavo B. Barra, Marie Togashi, Paul Webb, Francisco A. R. Neves, Noureddine Lomri, and Abderrahim Lomri

*Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 606, Lariboisière Hospital, and University of Paris, Paris, France (G.M.S., V.A., A.L.); Medical Research Council, Laboratory of Molecular Biology, Cambridge, United Kingdom (G.M.S.); Molecular Pharmacology Laboratory, Department of Pharmaceutical Sciences, School of Health Sciences, University of Brasília, Brasília, Brazil (G.B.B., M.T., F.A.R.N.); Diabetes Center and Department of Medicine, University of California School of Medicine, San Francisco, California (M.T., P.W.); and University of Cergy-Pontoise, Unité de Formation et de Recherche des Sciences et Techniques, GRP2H-INSERM Unité 680, Département de Biologie, Cergy-Pontoise, France (G.M.S., N.L.)*

Received April 12, 2006; accepted May 30, 2006

## ABSTRACT

The role of thyroid hormone [L-3,5,3'-triiodothyronine ( $T_3$ )] and the thyroid hormone receptor (TR) in regulating growth, development, and metabolic homeostasis is well established. It is also emerging that  $T_3$  is associated with oxidative stress through the regulation of the activity of superoxide dismutase-1 (SOD-1), a key enzyme in the metabolism of oxygen free radicals. We found that  $T_3$  reverses the activation of the SOD-1 promoter caused by the free radical generators paraquat and phorbol 12-myristate 13-acetate through the direct repression of the SOD-1 promoter by liganded TR. Conversely, the SOD-1 promoter is significantly stimulated by unliganded TRs. This

regulation requires the DNA-binding domain of the TR, which is recruited to an inhibitory element between –157 and +17 of the SOD-1 promoter. TR mutations, which abolish recruitment of coactivator proteins, block repression of the SOD-1 promoter. Conversely, a mutation that inhibits corepressor binding to the TR prevents activation. Together, our findings suggest a mechanism of negative regulation in which TR binds to the SOD-1 promoter but coactivator and corepressor binding surfaces have an inverted function. This effect may be important in  $T_3$  induction of oxidative stress in thyroid hormone excess.

Thyroid hormones control growth, development, and metabolism in virtually all mammalian tissues. Indeed, a pri-

mary role of L-3,5,3'-triiodothyronine ( $T_3$ ) is to regulate oxygen consumption and metabolic rate (Yen, 2001; Baxter and Webb, 2006). More recently it has emerged that thyroid hormones are associated with the induction of oxidative stress in certain tissues. In fact, the hypermetabolic state in hyperthyroidism is associated with oxidative tissue injury, including alterations of heart electrical activity, muscle weakness, and liver injury (Venditti and Meo, 2006).

Oxidative injury is normally limited through the activity of the superoxide dismutase (SOD) enzymes, which serve as the first line of defense against the damaging effects of superoxide radicals ( $O_2^-$ ) by convert  $O_2^-$  to hydrogen peroxide. Of the

This work was supported in part by Ministry of Education of Brazil, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)-Comité Français d'Evaluation de la Coopération Universitaire avec le Brésil program grant 434/03 (to F.A.R.N., N.L., and A.L.) and by Brazilian Research Council (Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)/Programa de Apoio ao Desenvolvimento Científico e Tecnológico Subprograma de Biotecnologia 620003/02-2 and CNPq 40.00.43/02-5). G.M.S. was supported by a CAPES postdoctoral fellowship.

F.A.R.N., N.L., and A.L. share senior authorship.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.106.025627.

**ABBREVIATIONS:**  $T_3$ , L-3,5,3'-triiodothyronine; SOD, superoxide dismutase; TR, thyroid hormone receptor; TRE, thyroid hormone response element; GRIP, glucocorticoid receptor-interacting protein; SRC-1, steroid receptor coactivator-1; PMA, phorbol 12-myristate 13-acetate; GST, glutathione S-transferase; HTC, hepatoma tissue culture; DTT, dithiothreitol; SMRT, silencing mediator for retinoid and thyroid receptors; TST, Tris/saline/Tween 20; TRH, thyrotropin-releasing hormone; TSH, pituitary thyroid-stimulating hormone; DBD, DNA binding domain; wt, wild-type; RTH, resistance to thyroid hormone; F451X, deletion of helix 12; G345R, mutation in the ligand binding domain; GS125, mutation in the DBD; I280K, mutation in the corepressor binding site; GAL-4 TR $\beta$ 1, chimerical TR consisting of the TR $\beta$ 1LBD fused to GAL-4 DBD.

different SOD enzymes, SOD-1 is the most abundant (90%) and is widely distributed (Johnson and Giulivi, 2005). *Drosophila melanogaster* that lack SOD-1 shows a reduced life span (Phillips et al., 1989). Moreover, perturbations in SOD-1 activity have been associated with several diseases (Peled-Kamar et al., 1995; Stathopoulos et al., 2003).

The antioxidant defense system is influenced by the thyroid hormone status. For example, thyroxine treatment decreases Cu/Zn SOD (SOD-1) activity in the liver of old rats (Saicic et al., 2006). Conversely, progressive hypothyroidism leads to an increase of superoxide dismutase activity in the brain of rats (Rahaman et al., 2001). cDNA microarray experiments to identify genes perturbed in hyperthyroid rat hearts revealed a number of genes, including SOD-1, that were down-regulated by  $T_3$  (De et al., 2004). Although the inverse association between SOD-1 and  $T_3$  in several tissues was clear, the mechanism involved in this regulation remained poorly understood.

The genomic actions of thyroid hormone are mediated by TRs, which are ligand-regulated transcription factors belonging to the nuclear receptor superfamily (McKenna and O'Malley, 2002; Nettles and Greene, 2005). The molecular mechanism of positive transcriptional regulation by TR is well established. TRs interact directly with specific DNA sequences, known as thyroid hormone response elements (TREs) (Yen et al., 2006). Unliganded TRs recruit specific corepressor proteins that, in turn, form part of a large corepressor complex that contains histone deacetylases and represses transcription of nearby genes by condensing chromatin (Li et al., 2000; McKenna and O'Malley, 2002; Codina et al., 2005). Ligand binding induces changes in receptor conformation and dynamics (Nagy and Schwabe, 2004) that lead to the release of corepressors and subsequent recruitment of p160 coactivators, such as glucocorticoid receptor-interacting protein (GRIP1) and steroid receptor coactivator-1 (SRC-1) (Ribeiro et al., 1998).

In contrast to positive regulation, the molecular mechanism of negative regulation by nuclear receptors is less well understood. Several hypotheses have been proposed to explain the action of TR on negative TREs (Lazar, 2003). One hypothesis is that the TR directly regulates transcription through direct binding to target promoters, either to unusual DNA response elements or via protein-protein interactions with other transcription factors associated with cognate response elements. Another hypothesis suggests that the role of TR is indirect through the squelching of coregulators from other transcription factors.

In this study, we sought to understand the mechanism through which  $T_3$  regulates the proximal region of the SOD-1 gene promoter. We showed that  $T_3$  could reverse the activation of the SOD-1 promoter caused by free radical generators, such as paraquat and PMA. We observed that TR $\beta$ 1 (and also TR $\alpha$ 1) activates SOD-1 promoter in the absence of ligand, and  $T_3$  reversed this activation in a dose-dependent manner. We found that the region of the SOD-1 promoter between -157 and the +17 was essential for TR $\beta$ 1 regulation, and this regulation requires the TR DNA binding domain for binding to the proximal region of the SOD-1 promoter. TR mutants that were defective in corepressor recruitment no longer activated the SOD-1 promoter. Conversely, a receptor that was defective in coactivator recruitment, but was still able to interact with corepressor, showed impaired down-


regulation in response to  $T_3$ . We therefore suggest that TR may play a role in oxidative stress by directly binding to the SOD-1 promoter, but TR coregulator binding surfaces have an inverted function. This effect may be important in production of intracellular superoxide radicals in conditions of thyroid hormone excess.

## Materials and Methods

**Plasmids.** The TR mutants F451X, G345R, and GS125 TR $\beta$ 1 were created with the use of QuikChange site-directed mutagenesis kits (Stratagene, La Jolla, CA) into the pCMX vector that encodes 461 amino acids of hTR $\beta$ 1 sequence. The mutated sequence was verified by DNA sequencing using Sequenase kits (Stratagene). The five deletions of SOD-1 promoter cloned upstream of the luciferase gene (Minc et al., 1999) were kindly provided by Dr. Christian Jaulin [Centre de Recherche en Cancérologie (E229), Montpellier, France]. Plasmids encoding hTR $\beta$ 1 (Ribeiro et al., 2001) Gal-4 hTR $\beta$ 1, GAL-responsive element-5 Luciferase, GST-GRIP1 (563–767) (Darimont et al., 1998), GST-SRC1a (381–882) (Feng et al., 1998), GST-SMRT (987–1491) (Webb et al., 2003), and TR mutant I280K (Marimuthu et al., 2002) were gifts from Dr. J. D. Baxter (University of California, San Francisco, CA).

**Cell Culture and Transfection.** U937, MG63, and rat hepatoma tissue culture (HTC) cells were maintained and subcultured in RPMI-1640 medium or Dulbecco's modified Eagle medium, containing 5% fetal calf serum, 50 units/ml penicillin, 50  $\mu$ g/ml streptomycin, at 37°C and 5%  $CO_2$ . Transfection procedures were described previously (Ribeiro et al., 2001), with some modifications. In brief, MG63 and HTC cells were divided 48 h before transfection to generate 40 to 60% confluence in 150-mm plates at the time of transfection. Cells were collected by centrifugation and then resuspended in transfection solution ( $1.5 \times 10^7$  cells/0.5 ml) containing DMEM without phenol red (Invitrogen, Carlsbad, CA) and 250 mM sucrose, and then cotransfected with 3  $\mu$ g of SOD-1 luciferase reporter gene, 500 ng of control  $\beta$ -galactosidase vector and 1.5 to 4.5  $\mu$ g of wtTR $\beta$ 1 expression vector or its mutants. Cells were transferred to a cuvette and then electroporated by using a Bio-Rad gene pulser under 290 mV and 960  $\mu$ F. After electroporation, cells were transferred to fresh media and then plated in 12-well multiplates and treated with  $T_3$  ( $10^{-7}$  M or different concentrations) or ethanol (control). After 24 h, cells were collected by centrifugation, lysed by the addition of 150  $\mu$ l of 1 $\times$  lysis buffer (Promega), and assayed for luciferase and  $\beta$ -galactosidase activity (kit from Promega Corp.). Transfection data are mean  $\pm$  S.E.M. of a minimum of triplicate samples that were repeated three to five times. The empty vector pCMX was used as a control for the transfections without TR (Fig. 1B). Because we noticed no difference between transfections with SOD-1 promoter alone and cotransfections with empty pCMX vector (data not shown), some assays were performed in absence of pCMX.

**Gel Shift Assay.** Binding of TR to DNA was assayed by mixing 20 fmol of  $^{35}$ S-labeled TR $\beta$ 1 or GS125 TR $\beta$ 1 produced in a reticulocyte lysate system, TnT T7 (Promega, Madison, WI), in the presence or absence of  $10^{-6}$  M  $T_3$ , with 600 fmol of unlabeled different SOD-1, DR-4 (5'-AGTTC AGGTCA CAGG AGGTCA GAG-3') and inverted palindrome F2 (5'-TTC TGACCC CATTGG AGGTCA-3') oligonucleotides, and 1  $\mu$ g of poly(dI-dC) (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in a 20- $\mu$ l reaction mixture. The binding buffer contained 25 mM HEPES, 50 mM KCl, 1 mM DTT, 10  $\mu$ M  $ZnSO_4$ , 0.1% Nonidet P-40, and 5% glycerol. After 30 min at room temperature, the mixture was loaded onto a 5% nondenaturing polyacrylamide gel that was previously run for 30 min at 200 V. To visualize the TR-DNA complexes, the gel was run at 4°C for 120 min at 240 V, in a running buffer containing 6.7 mM Tris, pH 7.5, 1 mM EDTA, and 3.3 mM sodium acetate. The gel was then fixed, treated with Amplify (GE Healthcare), dried and exposed for autoradiography. TRs used in this assay were quantified through [ $^{125}$ I] $T_3$  binding



**Fig. 1.** Regulation of SOD-1 by thyroid hormone receptor. A, human promonocytic U937 cells were cotransfected with 3  $\mu$ g of a reporter gene containing a construction pGLS -1499 SOD-1 promoter encoding luciferase (SOD-1 Luc) and treated or not with 50  $\mu$ M paraquat; \*,  $P < 0.001$  versus no TR; \*\*,  $P < 0.001$  versus no T<sub>3</sub>. B, U937 cells were cotransfected with 1.5, 3.0, and 4.5  $\mu$ g of expression vector encoding wt hTR $\beta$ 1 and 3  $\mu$ g of -1499 SOD-1 Luc; \*,  $P < 0.001$  versus TR no T<sub>3</sub>; \*\*,  $P < 0.001$  versus no TR/no T<sub>3</sub>; \*\*\*,  $P < 0.01$  versus not with 50  $\mu$ M paraquat; #,  $P < 0.01$ ; ##,  $P < 0.001$ . C, U937 cells were cotransfected with 1.5  $\mu$ g of wt hTR $\beta$ 1 and 3  $\mu$ g of -1499 SOD-1 Luc and then treated with increasing amounts of T<sub>3</sub>; \*,  $P < 0.001$  versus no T<sub>3</sub>. Luciferase activity was expressed as percentage of -1499 SOD-1 Luc in the absence of T<sub>3</sub> and without or with cotransfected wt hTR $\beta$ 1.

assay. Amounts used for gel shift assay were also confirmed through SDS-PAGE run of <sup>35</sup>S-labeled TRs, where gels were fixed, dried, and exposed for autoradiography. Bands visualized in X-ray films were quantified with a Kodak imager (Eastman Kodak, Rochester, NY). SOD-1 oligonucleotides (Fig. 4A): Seq1 (-87 to -46), GAGCGCGT-GCGAGGCGATTGGTTTGGGGCCAGAGTGGGCGAG; Seq1mut (in bold; -87 to -46), GAGCGCGTGGCGAGGCGATTGGATGCGATGCC-AGAGTGGGCGAG; Seq 2 (-51 to -7), GGCGAGGCGCGGAGGTC-TGGCCTATAAAGTAGTCGCGGAGACGGG; Seq 3 (-12 to +29), GACGGGGTGCTGGTTTGCCTCGTAGTCTCCTGCAGCGTCTGG; Seq 4 (+23 to +69), TCTGGGGTTTCCGTTGCAGTCTCCTCGGAACC-AGGACCTCGGCGTG; and Seq 5 (+64 to +104), GGCGTGGCCTA-GCGAGTTATGGCGACGAAGGCCCGTGTGCG.

**GST Pull-Down Assay.** pCMX-TR $\beta$ 1wt or pCMX-mutants vectors were used to produce radiolabeled full-length receptor in vitro, using the TNT-Coupled Reticulocyte Lysate System (Promega) and [<sup>35</sup>S]methionine. GST SRC1a (381–882), GST-GRIP1 (563–767), and GST-SMRT (987–1491) fusion proteins were prepared using conventional protocols (Pfizer, New York, NY). In brief, the plasmids were transformed into BL21, cultured into 2xLB medium, pelleted and resuspended in 1 $\times$  TST buffer (50 mM Tris pH 7.5, 150 mM NaCl, and 0.05% Tween 20) with 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail 1:1000 (Sigma, St. Louis, MO). Then, the solution was incubated with lysozyme and sonicated (three 2.5-min cycles, amplitude 70%, 1 pulse/s with a break of 5 min between each cycle).

The debris were pelleted and the supernatant was incubated for 2 h with 500  $\mu$ l of glutathione-Sepharose 4B beads equilibrated with 1 $\times$  TST. GST fusion protein beads were washed with 1 $\times$  TST containing 0.05% Nonidet P-40 and resuspended in 1 $\times$  TST with 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail 1:1000 (Sigma), and 50% glycerol, and then stored at -20°C. All procedures above were carried out at 4°C. For the binding assay, the glutathione bead suspension containing 4  $\mu$ g of GST fusion protein was incubated with 3  $\mu$ l of <sup>35</sup>S-labeled protein in 150  $\mu$ l of 1 $\times$  TST buffer with 0.1% Nonidet P-40, 0.1% Triton X-100, 1 mM DTT, and 2  $\mu$ g/ml bovine serum albumin, in the presence of 10<sup>-6</sup> M T<sub>3</sub> or vehicle. After a 2-h incubation at 4°C, the beads were washed with the same incubation buffer. The beads with associated proteins were analyzed on 10% SDS-polyacrylamide gels and visualized by autoradiography.

**Statistical Analysis.** One-way analysis of variance followed by Student-Newman-Keuls multiple comparison test was employed for assessment of significance (Prism version 4.0a; GraphPad Software Inc., San Diego, CA). Differences were considered to be significant at  $P < 0.05$ .

## Results and Discussion

**The SOD-1 Promoter Is Negatively Regulated by TR $\beta$ 1/T<sub>3</sub>.** To explore the regulation of the proximal SOD-1 gene, we used a reporter plasmid with the proximal promoter region -1499 to +17 of the SOD-1 fused to the luciferase gene (SOD-luc). Here, we observe that treatment with T<sub>3</sub>, the active thyroid hormone, reversed the effect of the paraquat through a direct or indirect repression of the SOD-1 promoter activity (Fig. 1A).


To determine whether the effect of T<sub>3</sub> on the SOD-1 promoter was mediated by the TR, we examined the effect of transfected TR $\beta$ 1 on the SOD-1 promoter activity in U937 cells (Fig. 1, B and C), human osteosarcoma MG63 cells (data not shown) and rat HTC cells (Fig. 3B) in the presence or absence of T<sub>3</sub>. We observed that unliganded TR $\beta$ 1, also TR $\alpha$ 1 (data not shown), activated the SOD-1 promoter and that T<sub>3</sub> reversed this effect. TR $\beta$ 1 activated the SOD-1 promoter in U937 cells by 2- to 3-fold in a concentration-dependent man-



ner, and  $T_3$  treatment reversed this activation by 50 to 60% (Fig. 1B).  $T_3$  repression was dose-dependent (Fig. 1C), with maximum inhibitory effect at 0.5 nM, typical for thyroid hormone responses.

The SOD-1 promoter behaved similarly to those of thyrotropin-releasing hormone (TRH) (Feng et al., 1994) and the pituitary thyroid-stimulating hormone (TSH)  $\alpha$ - and  $\beta$ - subunit genes (Chatterjee et al., 1989; Bodenner et al., 1991), which all contain nTREs.

**A  $T_3$ -Responsive Sequence in SOD-1 Promoter.** To characterize the element responsible for unliganded TR $\beta$ 1




**Fig. 2.** TR $\beta$ 1 activation and  $T_3$  inhibition in different 5' deletions of the SOD-1 promoter linked to the luciferase gene. U937 cells were cotransfected with 1.5  $\mu$ g of expression vector encoding hTR $\beta$ 1wt and 3  $\mu$ g of different pGLS constructs of SOD-1 promoter encoding luciferase; \*,  $P < 0.001$  versus no  $T_3$ ; \*\*,  $P < 0.05$  versus no  $T_3$  (A) or with -157 SOD1 Luc, treated or not with 100 ng/ml PMA; \*,  $P < 0.001$  versus no PMA/no  $T_3$ ; \*\*,  $P < 0.001$  versus PMA/no  $T_3$  (B). The data show a representative experiment, which was repeated 3–4 times.

activation and  $T_3$  inhibition in the SOD-1 proximal promoter, we examined effects of  $T_3$  upon different 5' deletions of the SOD-1 promoter. Constructs with a 5' boundary of pGLS -157 or longer were repressed by  $T_3$  (Fig. 2A). The shorter construct pGLS -71/+17 also showed a significant response to  $T_3$  treatment but the constitutive activity of the promoter was so much lower that one could not be fully confident that the full  $T_3$  response was preserved. Together, these results suggest that a  $T_3$  response element is located in the nucleotide -157 to +17 region.

To confirm the opposing activities of free radical generator and  $T_3$  on the -157/+17 SOD-1 promoter, we tested the effect of PMA on SOD-1 Luc construct cotransfected with TR $\beta$ 1. As expected, PMA activated this promoter and  $T_3$  antagonized this effect (Fig. 2B).

**The DBD of TR Was Required to Regulate the SOD-1 Promoter.** To understand whether the regulatory effect of the TR on the activity of the SOD-1 promoter required TR $\beta$ 1 DNA-binding domain, we examined the activity of a chimeric TR lacking the DNA binding domain (DBD) but fused to the heterologous GAL-4 DBD (GAL-4 TR $\beta$ 1) (Fig. 3A). This chimeric protein showed a lower activation of the SOD-1 pro-



**Fig. 3.** DBD is required to regulate SOD-1 promoter. A, U937 cells were cotransfected with 3  $\mu$ g of -1499 SOD-1 Luc and 1.5  $\mu$ g of GAL-4 TR $\beta$ 1 or wt hTR $\beta$ 1; \*,  $P < 0.001$  versus no TR/no  $T_3$ ; \*\*,  $P < 0.001$  versus TR/no  $T_3$ ; \*\*\*,  $P < 0.001$ . B, HTC cells were cotransfected with 3  $\mu$ g of pGLS -157 SOD-1 Luc and 1.5  $\mu$ g of TR $\beta$ 1 or GS125 hTR $\beta$ 1; \*,  $P < 0.001$  versus no TR/no  $T_3$ ; \*\*,  $P < 0.001$  versus TR/no  $T_3$ ; \*\*\*,  $P < 0.001$ . The data show a representative experiment that was repeated three or four times.




motor compared with wtTR and did not repress SOD-1 promoter in the presence of  $T_3$ . GAL-4 TR $\beta$ 1 did activate GAL luciferase reporter gene in presence of  $T_3$  (data not shown), indicating that this protein was functionally active. In addition, we prepared and analyzed the activity of a TR $\beta$ 1 mutant, GS125, as described previously for TR $\beta$ 2 (Shibusawa et al., 2003b). This mutant did not regulate the -157 SOD-1 promoter (Fig. 3B) but showed the same binding affinity to  $T_3$  as wt TR $\beta$ 1/ $T_3$ , confirming that it was functional (data not shown).

Nuclear receptors regulate transcription by binding to specific DNA sequences in target genes but can also modulate gene expression by mechanisms independent of DNA binding. Analysis of the "knock-in" mouse that harbors a TR $\beta$  mutant defective in DNA binding described by Shibusawa et al. (2003a) revealed that thyroid hormone failed to suppress


TSH gene transcription in these mice, supporting the conclusion that negative regulation of the TSH gene required DNA binding by TR. Our data indicate that two TR mutants that cannot bind to canonical TREs, GAL-4 TR $\beta$ 1 and GS125 TR $\beta$ 1, both failed to repress SOD-1 promoter activity. The GS125 TR $\beta$ 2 mutant, which binds to a TRE/glucocorticoid response element promoter but showed low affinity for positive and negative TREs, abolishes transactivation on three classic pTREs (DR4, LAP, and PAL) and all negatively regulated promoters in the hypothalamic-pituitary-thyroid axis (TRH, TSH $\beta$ , and TSH $\alpha$ ) (Shibusawa et al., 2003b). Thus, our results suggest that TR DNA binding activity is required for regulation of the SOD-1 promoter.

**TR $\beta$ 1 Bound to SOD-1 Promoter.** To test the hypothesis that TR binds to the SOD-1 promoter, we performed gel-shift assays with radiolabeled TR $\beta$ 1 and different sequences from

Seq 1 (-87 to -46): GAGCGCGTGCAGGCGATTGGTTTGGGGCCAGAGTGGGCGAG  
 Seq 1mut (-87 to -46): GAGCGCGTGCAGGCGATTGGATGCATGCCAGAGTGGGCGAG  
 Seq 2 (-51 to -7): GGCAGGGCGCGGAGGTCTGGCCTATAAAGT GTCGCGGAGACGGG  
 Seq 3 (-12 to +29): GACGGGGTGCTGGTTTGCCTCGTAGTCTCCTGCAGCGTCTGG  
 Seq 4 (+23 to +69): GTCTGGGGTTTCCGTTGCAGTCCTCGGAACAGGACCTCGGCGTG  
 Seq 5 (+64 to +104): GGCGTGGCCTAGCGAGTTATGGCGACGAAGGCCGTGTGCG



**Fig. 4.** TR $\beta$ 1 binds to different sequence of SOD-1 promoter. Gel-shift assays contained 20 fmol of the in vitro-translated  $^{35}$ S-labeled hTR $\beta$ 1 (A-C),  $^{35}$ S-labeled GS125 TR mutant (B and C) and 600 fmol of DR4 (A, lanes 5 and 6; B, lanes 1-4; C, lanes 1 and 2), F2 (A, lanes 3 and 4), different sequences of SOD-1 (A, lanes 7-16), or only the sequence 1 of SOD-1, mutated (B, lanes 5 and 6) or not mutated (B, lanes 7 and 8; C, lanes 5-6).



the SOD-1 promoter and the first exon of SOD-1 gene (Fig. 4A). As expected, the TRβ1 bound as a homodimer to two canonical positive TREs (F2 and DR4) in the absence of ligand, and T<sub>3</sub> shifted the balance toward monomer binding (Fig. 4A, lanes 3–6). Three regions of the SOD-1 sequence supported weak TRβ1 binding. The sequence 1 of SOD-1 promoter (–87 to –46) binds monomeric TR, and this binding was slightly increased in the presence of T<sub>3</sub> (Fig. 4A, lanes 7 and 8). Sequences from the first exon of SOD-1 transcript (+23 to +69 and +64 to +104) support weak homodimer and monomer binding (Fig. 4A, lanes 13–16); T<sub>3</sub> favored TR monomer formation (Fig. 4A, lanes 14 and 16). Interestingly we noticed that TRβ1 bound rather weakly to the SOD-1 promoter compared with DR4 or F2 elements.

The sequence –87 to –46 of SOD-1 promoter is close to the TATA box region and contains the sequence TTTGGG, which is also present in other negatively regulated genes characterized previously (Kim et al., 2005). Mutation of this sequence (ATGCAT) abolished TR monomer binding (Fig. 4B, lanes 5–8). Moreover, the GS125 TRβ1 mutant, which cannot regulate SOD-1 activity, was also unable to bind to the DR-4 element or SOD-1 sequences (Fig. 4, B, lanes 3 and 4, and C). Both lines of evidence suggest that TR regulated SOD-1 activity by binding to the sequence 1 negative TRE.

These results are in accordance with other studies, which showed the presence of nTREs in the promoters very close to the TATA box (Belandia et al., 1998; Perez-Juste et al., 2000). It is noteworthy that TR also binds weakly to two different sequences in the first exon of SOD-1 gene; here, unliganded TR bound as homodimers and liganded TR as monomer units. Belandia et al. proposed that T<sub>3</sub> represses β-amyloid precursor protein promoter activity by a mechanism that requires binding of TR to a specific sequence located in the first exon (Belandia et al., 1998).

The TR-DNA interaction observed in our study is weak compared with other positive TREs, F2 and DR4. Nevertheless, nTREs are generally composed of weak TR binding sites. Kim et al. (2005) demonstrated that nuclear receptor corepressor activates CD44 promoter by a weak unliganded TR-DNA interaction, 100-fold less than DR4. This weak TR-DNA binding was essential for CD44 regulation by T<sub>3</sub>. Our results are in agreement with this finding, in that they showed a weak TR-SOD-1 promoter interaction.

Although our data indicate that TR monomer units were important for the repression mechanism of SOD-1 promoter by T<sub>3</sub>, we cannot exclude the idea that squelching of coregulators might have played a part in this regulation. Our results reveal that GAL-4 TR did activate the SOD-1 promoter in the absence of hormone to a significant degree. Because the ligand binding domain of Gal-4 TR can bind to coregula-

**Fig. 5.** TRβ1 mutations in coactivator and corepressor binding surfaces. A, pull-down experiments examining the binding of labeled receptors to SMRT, GRIP, and SRC protein fragment. Binding is expressed as the percentage of input labeled receptor. Binding of <sup>35</sup>S-labeled wt hTRβ1 or F451X to GST-SMRT, GST-SRC, and GST-GRIP in presence or absence of 10<sup>-6</sup> M T<sub>3</sub>. U937 cells were cotransfected with 3 μg of pGLS –157 SOD-1 Luc and 1.5 μg of wt hTRβ1 or F451X (B), \*, *P* < 0.001 versus no TR/no T<sub>3</sub>; \*\*, *P* < 0.001 versus TR/no T<sub>3</sub>; \*\*\*, *P* < 0.001; G345R (C), \*, *P* < 0.001 versus TR/no T<sub>3</sub>; or I280K (D), \*, *P* < 0.001 versus no TR; \*\*, *P* < 0.001 versus TR/no T<sub>3</sub>; \*\*\*, *P* < 0.01. B and C, luciferase activity was expressed as percentage of –157 SOD-1 Luc in the absence of T<sub>3</sub> and without (B) or with (C) cotransfected wt hTRβ1. D, the data show a representative experiment that was repeated three to five times.



tors, it is possible that the squelching mechanism could contribute to activation by unliganded TRs. Furthermore, indirect regulation through other transcription factors may cooperate with liganded TR to negatively regulate the SOD-1 promoter, because the -157 to +17 region in this promoter shows binding sites for the transcription factors: simian virus 40 promoter factor 1, activator protein-1, early growth response protein, nuclear factor- $\kappa$ B, and aryl hydrocarbon receptor. Of these, it has been well established that AP-1 can be subject to "trans-repression" by nuclear receptors. Therefore, we tested whether a mutation to the AP-1 site might reduce the activity of TR on this promoter (data not shown). Our results clearly showed that this was not the case.

**Activation of the SOD-1 Promoter by Unliganded TR Requires the Corepressor Binding Surface.** To explore the role of TR coregulator binding surfaces in SOD-1 promoter regulation, we made use of mutations that have been characterized previously. We first confirmed that a natural mutation of the TR (F451X) in which helix 12 is absent, from patients with resistance to thyroid hormone (RTH), increases TR binding to corepressor nuclear receptor corepressor (Marimuthu et al., 2002) in GST pull-down assays. In this study, we showed that  $T_3$  decreases the binding of TR to the corepressor SMRT (Fig. 5A, wtTR lane 5) and increases binding to the coactivators GRIP and SRC (Fig. 5A, wtTR lanes 7 and 9). Furthermore, F451X shows an enhanced constitutive binding to SMRT (Fig. 5A, F451X lanes 4 and 5) and decreased binding to both coactivators (Fig. 5A, F451X lanes 6–9). In transfection assays, F451X increased Luc expression from the SOD-1 promoter by 2.2-fold and  $T_3$  could not reverse this activation (Fig. 5B).

We also analyzed the actions of another RTH mutant (G345R), which binds corepressor (Liu et al., 1998) but cannot bind ligand (Yen et al., 1995; Takeshita et al., 1996), on SOD-1 promoter activity. Like F451X, G345R activated the -157 SOD-1 promoter but failed to repress the SOD-1 promoter in presence of  $T_3$  (Fig. 5C). Together, these results indicate that two TR $\beta$ 1 mutants that bind corepressors but not coactivators can enhance SOD-1 promoter activity.

Previous studies indicate that corepressors may be involved in activation of genes negatively regulated by thyroid hormone, such as TSH $\beta$ , TSH $\alpha$ , and TRH (Tagami et al., 1999; Berghagen et al., 2002). Our results are in agreement with these findings. The natural mutant F451X, where the helix 12 of wtTR was deleted and the corepressor-binding surface was exposed, enhances corepressor and inhibits coactivator binding and stimulates the SOD-1 promoter more strongly than wtTR $\beta$ 1, and  $T_3$  did not reverse this effect. Likewise, another RTH mutant that binds corepressor but not ligand or coactivator activated the SOD-1 promoter better than wtTR $\beta$ 1 and, as expected, failed to repress transcription in response to  $T_3$ .

To investigate the role of the corepressor binding surface in SOD-1 promoter regulation, we used a previously characterized TR mutant that inhibit corepressor binding (Marimuthu et al., 2002). One of the residues that forms the corepressor-binding surface, Ile280, lies mostly underneath helix 12 and is solvent-inaccessible in the liganded TR-ligand binding domain structure. The mutant I280K (G. B. Barra, L. F. Ribeiro-Velasco, R. Pessanha, I. C. Ribeiro, L. A. Simeoni, R. C. J. Ribeiro, F. A. R. Nerves, manuscript in preparation) showed a decreased SMRT binding and also a weak binding

to GRIP and SRC in presence of  $T_3$ . The unliganded TR I280K mutant activated neither the SOD-1 promoter nor wtTR $\beta$ 1 in transfections (Fig. 5D) and did not repress SOD-1 promoter activity in the presence of  $T_3$ . Together, our data indicate that the corepressor binding surface was required for activation of the SOD-1 promoter by unliganded TRs and that the coactivator binding surface was required for  $T_3$ -dependent repression. These results indicate that the role of TR corepressor and coactivator binding surfaces was reversed at the SOD-1 promoter.

It is presently believed that nuclear hormone receptors promote dynamic recruitment of different coregulator complexes to target promoters and that these effects are associated with an equally dynamic binding of the nuclear receptor itself to the promoter (Perissi and Rosenfeld, 2005). In this context, further studies will be important to elucidate the dynamic mechanism of the recruitment of multiple complexes, such as histone deacetylases/corepressors/TR, to alter the chromatin structure surrounding the promoter of SOD-1 gene. Nevertheless, our data support the hypothesis of an inverted role of coregulators on negative TREs.

In conclusion, we have revealed the SOD-1 promoter as a novel target for TR action. Given that SOD-1 is a key enzyme against the damaging effects of superoxide radicals, this closely associates the thyroid hormone and the formation of oxygen radicals and other reactive species, which lead to oxidative stress. In addition, this study highlights the SOD-1 promoter as a useful tool for studying genes that are negatively regulated by thyroid hormone, providing new insights into the negative regulation by nuclear hormone receptors.

#### Acknowledgments

We are grateful to John Schwabe for helpful discussions and reviewing the manuscript. We thank John D. Baxter for providing clones of TR $\beta$ 1 and mutants and Christian Jaulin for clones of SOD-1Luciferase.

#### References

- Baxter JD and Webb P (2006) Metabolism: bile acids heat things up. *Nature (Lond)* **439**:402–403.
- Belandia B, Latasa MJ, Villa A, and Pascual A (1998) Thyroid hormone negatively regulates the transcriptional activity of the  $\beta$ -amyloid precursor protein gene. *J Biol Chem* **273**:30366–30371.
- Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, and Saatcioglu F (2002) Corepressor SMRT functions as a coactivator for thyroid hormone receptor TR $\alpha$  from a negative hormone response element. *J Biol Chem* **277**:49517–49522.
- Bodenner DL, Mroczynski MA, Weintraub BD, Radovick S, and Wondisford FE (1991) A detailed functional and structural analysis of a major thyroid hormone inhibitory element in the human thyrotropin beta-subunit gene. *J Biol Chem* **266**:21666–21673.
- Chatterjee VK, Lee JK, Rentoumis A, and Jameson JL (1989) Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. *Proc Natl Acad Sci USA* **86**:9114–9118.
- Codina A, Love JD, Li Y, Lazar MA, Neuhaus D, and Schwabe JW (2005) Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors. *Proc Natl Acad Sci USA* **102**:6009–6014.
- Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, and Yamamoto KR (1998) Structure and specificity of nuclear receptor-coactivator interactions. *Genes Dev* **12**:3343–3356.
- De K, Ghosh G, Datta M, Konar A, Bandyopadhyay J, Bandyopadhyay D, Bhattacharya S, and Bandyopadhyay A (2004) Analysis of differentially expressed genes in hyperthyroid-induced hypertrophied heart by cDNA microarray. *J Endocrinol* **182**:303–314.
- Feng P, Li QL, Satoh T, and Wilber JF (1994) Ligand ( $T_3$ ) dependent and independent effects of thyroid hormone receptors upon human TRH gene transcription in neuroblastoma cells. *Biochem Biophys Res Commun* **200**:171–177.
- Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, and West BL (1998) Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. *Science (Wash DC)* **280**:1747–1749.
- Johnson F and Giulivi C (2005) Superoxide dismutases and their impact upon human health. *Mol Aspects Med* **26**:340–352.
- Kim SW, Ho SC, Hong SJ, Kim KM, So EC, Christoffolete M, and Harney JW (2005)

- A novel mechanism of thyroid hormone-dependent negative regulation by thyroid hormone receptor, nuclear receptor corepressor (NCoR), and GAGA-binding factor on the rat cD44 promoter. *J Biol Chem* **280**:14545–14555.
- Lazar MA (2003) Thyroid hormone action: a binding contract. *J Clin Invest* **112**: 497–499.
- Li J, Wang J, Nawaz Z, Liu JM, Qin J, and Wong J (2000) Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. *EMBO (Eur Mol Biol Organ) J* **19**:4342–4350.
- Liu Y, Takeshita A, Misiti S, Chin WW, and Yen PM (1998) Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. *Endocrinology* **139**:4197–4204.
- Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletterick RJ, Baxter JD, and West BL (2002) TR surfaces and conformations required to bind nuclear receptor corepressor. *Mol Endocrinol* **16**:271–286.
- McKenna NJ and O'Malley BW (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. *Cell* **108**:465–474.
- Minc E, de Coppel P, Masson P, Thiery L, Dutertre S, Amor-Gueret M, and Jaulin C (1999) The human copper-zinc superoxide dismutase gene (SOD1) proximal promoter is regulated by Sp1, Egr-1, and WT1 via non-canonical binding sites. *J Biol Chem* **274**:503–509.
- Nagy L and Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. *Trends Biochem Sci* **29**:317–324.
- Nettles KW and Greene GL (2005) Ligand control of coregulator recruitment to nuclear receptors. *Annu Rev Physiol* **67**:309–333.
- Peled-Kamar M, Lotem J, Okon E, Sachs L, and Groner Y (1995) Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. *EMBO (Eur Mol Biol Organ) J* **14**:4985–4993.
- Perez-Juste G, Garcia-Silva S, and Aranda A (2000) An element in the region responsible for premature termination of transcription mediates repression of *c-myc* gene expression by thyroid hormone in neuroblastoma cells. *J Biol Chem* **275**:1307–1314.
- Perissi V and Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. *Nat Rev Mol Cell Biol* **6**:542–554.
- Phillips JP, Campbell SD, Michaud D, Charbonneau M, and Hilliker AJ (1989) Null mutation of copper/zinc superoxide dismutase in *Drosophila* confers hypersensitivity to paraquat and reduced longevity. *Proc Natl Acad Sci USA* **86**:2761–2765.
- Rahaman SO, Ghosh S, Mohanakumar KP, Das S, and Sarkar PK (2001) Hypothyroidism in the developing rat brain is associated with marked oxidative stress and aberrant intraneuronal accumulation of neurofilaments. *Neurosci Res* **40**:273–279.
- Ribeiro RC, Apriletti JW, Wagner RL, West BL, Feng W, Huber R, Kushner PJ, Nilsson S, Scanlan T, Fletterick RJ, et al. (1998) Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. *Recent Prog Horm Res* **53**:351–392; discussion 392–394.
- Ribeiro RC, Feng W, Wagner RL, Costa CH, Pereira AC, Apriletti JW, Fletterick RJ, and Baxter JD (2001) Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. *J Biol Chem* **276**:14987–14995.
- Saacic ZS, Mijalkovic DN, Nikolic AL, Blagojevic DP, Spasic MB, and Petrovic VM (2006) Effect of thyroxine on antioxidant defense system in the liver of different aged rats. *Physiol Res*, in press.
- Shibusawa N, Hashimoto K, Nikrodhanond AA, Liberman MC, Applebury ML, Liao XH, Robbins JT, Refetoff S, Cohen RN, and Wondisford FE (2003a) Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo. *J Clin Invest* **112**:588–597.
- Shibusawa N, Hollenberg AN, and Wondisford FE (2003b) Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation. *J Biol Chem* **278**:732–738.
- Stathopoulos PB, Rummfeldt JA, Scholz GA, Irani RA, Frey HE, Hallelwell RA, Lepock JR, and Meiering EM (2003) Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. *Proc Natl Acad Sci USA* **100**:7021–7026.
- Tagami T, Park Y, and Jameson JL (1999) Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. *J Biol Chem* **274**:22345–22353.
- Takeshita A, Yen PM, Misiti S, Cardona GR, Liu Y, and Chin WW (1996) Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. *Endocrinology* **137**:3594–3597.
- Venditti P and Meo SD (2006) Thyroid hormone-induced oxidative stress. *Cell Mol Life Sci*.
- Webb P, Nguyen P, and Kushner PJ (2003) Differential SERM effects on corepressor binding dictate ER $\alpha$  activity in vivo. *J Biol Chem* **278**:6912–6920.
- Yen PM (2001) Physiological and molecular basis of thyroid hormone action. *Physiol Rev* **81**:1097–1142.
- Yen PM, Ando S, Feng X, Liu Y, Maruvada P, and Xia X (2006) Thyroid hormone action at the cellular, genomic and target gene levels. *Mol Cell Endocrinol* **246**: 121–127.
- Yen PM, Wilcox EC, Hayashi Y, Refetoff S, and Chin WW (1995) Studies on the repression of basal transcription (silencing) by artificial and natural human thyroid hormone receptor-beta mutants. *Endocrinology* **136**:2845–2851.

---

**Address correspondence to:** Abderrahim Lomri, INSERM Unité 606, Lariboisiere Hospital, 2, rue Ambroise Paré, 75475 Paris Cedex 10, France. E-mail: lomri@larib.inserm.fr

---